Replies to post #65 on Dusa Pharma (Dusa)

[surf1944]

3. DUSA Pharmaceuticals Inc. (DUSA): Develops and markets Levulan photodynamic therapy and other products for common skin conditions primarily in the United States, Canada, and Korea. Market cap at $135.58M. Price at $5.63. PEG at 0.85. Revenue grew by 28.54% during the most recent quarter ($15.27M vs. $11.88M y/y). Accounts receivable grew by 15.48% during the same time period ($3.73M vs. $3.23M y/y). Receivables, as a percentage of current assets, decreased from 12.2% to 10.31% during the most recent quarter (comparing 3 months ending 2011-12-31 to 3 months ending 2010-12-31).

http://seekingalpha.com/article/493441-5-undervalued-healthcare-stocks-with-positive-receivables-trends?source=yahoo